Table 1. Lesion confirmation of non-HCC benign lesions.

Non-HCC benign lesions	Confirmed by imaging and follow-up	Number of lesions
Hemangioma	Classic enhancement pattern on dynamic contrast-enhanced MRI, peripheral nodular enhancement in AP followed by progressive centripetal filling in the delay phase, and marked hyperintensity on T2-weighted MR imaging, without interval change during follow-up	35
APS	Isointensity on dynamic MRI other than AP images, isointensity on the HBP, and no change or a decrease in size during follow-up	28
FNH or FNH-like nodules	APHE plus iso- or hypersignal intensity during the portal-venous phase, at least partial hyperintensity compared to the liver parenchyma in the hepatobiliary phase, and no interval change	9
RN-DN	Hyperintensity on T1-weighted imaging and isointensity or hypointensity on T2-weighted imaging, isointensity in AP image or APHE without discernible “washout”, and no interval change during follow-up	32

HCC, hepatocellular carcinoma; AP, arterial phase; APS, arterioportal shunt; FNH, focal nodular hyperplasia; RN, regenerative nodule; DN, dysplastic nodule; AP, arterial phase; APHE, arterial phase hyperenhancement; HBP, hepatobiliary phase.